tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2013 Jun 26. [Epub ahead of print]
Inactivated and adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.
Source
Research Institute for Biological Safety Problems (RIBSP), Gvardeiskiy, Kazakhstan.
Abstract
In this study, we assessed the immunogenicity and safety of one dose (7.5 or 15 μg of hemagglutinin, HA) of a whole virion inactivated pre-pandemic influenza vaccine adjuvanted with aluminum hydroxide in humans. The vaccine strain was made by reverse genetics from the highly pathogenic avian A/chicken/Astana/6/05 (H5N1) clade 2.2 strain isolated from a dead bird in Kazakhstan. The humoral immune response was evaluated after a single vaccination by hemagglutination inhibition (HI) and micro neutralization (MN) assays. The vaccine was safe and immunogenic, inducing seroconversion in 55% of the evaluated patients with a geometric mean titer (GMT) of 17.1 and a geometric mean increase (GMI) of 3.42 in a dose of 7.5 μg in HI test against the vaccine strain. The rate of seroconversion increased up to 70% when the dose of 15 μg was used. A percentage of individuals achieving anti-HA titer ≥1:40 was 52.5% and 57.5% for the 7.5 and 15 μg dose groups, respectively. Similar results were obtained when antibodies were analyzed by an MN test. Substantial cross-neutralization titers (seroconversion in 35% and 52.5% of subjects in both dose groups, respectively) were detected against a heterologous clade 1 strain NIBRG14 (H5N1). Thus, one dose of this whole virion pre-pandemic vaccine adjuvanted with aluminum has the potential to be effective against H5N1 viruses of different clades.
PMID:
23803900
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23803900
Inactivated and adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.
Source
Research Institute for Biological Safety Problems (RIBSP), Gvardeiskiy, Kazakhstan.
Abstract
In this study, we assessed the immunogenicity and safety of one dose (7.5 or 15 μg of hemagglutinin, HA) of a whole virion inactivated pre-pandemic influenza vaccine adjuvanted with aluminum hydroxide in humans. The vaccine strain was made by reverse genetics from the highly pathogenic avian A/chicken/Astana/6/05 (H5N1) clade 2.2 strain isolated from a dead bird in Kazakhstan. The humoral immune response was evaluated after a single vaccination by hemagglutination inhibition (HI) and micro neutralization (MN) assays. The vaccine was safe and immunogenic, inducing seroconversion in 55% of the evaluated patients with a geometric mean titer (GMT) of 17.1 and a geometric mean increase (GMI) of 3.42 in a dose of 7.5 μg in HI test against the vaccine strain. The rate of seroconversion increased up to 70% when the dose of 15 μg was used. A percentage of individuals achieving anti-HA titer ≥1:40 was 52.5% and 57.5% for the 7.5 and 15 μg dose groups, respectively. Similar results were obtained when antibodies were analyzed by an MN test. Substantial cross-neutralization titers (seroconversion in 35% and 52.5% of subjects in both dose groups, respectively) were detected against a heterologous clade 1 strain NIBRG14 (H5N1). Thus, one dose of this whole virion pre-pandemic vaccine adjuvanted with aluminum has the potential to be effective against H5N1 viruses of different clades.
PMID:
23803900
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23803900